retatrutide trial phase Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal 3 obesity Eli Lilly infiltrates anti-obesity market

All three orforglipron groups had significantly greater improvements in multiple cardiometabolic risk factors than placebo, including waist circumference, fasting serum glucose, systolic blood pressure, lipids and high-sensitivity C-reactive protein

Room temperature storage, even for brief periods, accelerates degradation

Erythromycin is also subject to drug interactions with agents that alter or are metabolized by CYP3A4

COR-BMOD: In a 56-week trial, participants received 28 group counseling sessions, diet, and exercise goals

Your provider may recommend switching from Contrave to Wegovy (or vice versa) depending on how you respond to treatment